{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:29:16Z","timestamp":1770474556763,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Photosensitivity (PSN) is a common initial symptom of systemic lupus erythematosus (SLE). This study compared the clinical characteristics of PSN-SLE and non-PSN-SLE patients, analyzed their phenotypic differences and PSN-associated factors, and explored the diagnostic value of PSN for early SLE identification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis was conducted on clinical data of SLE patients hospitalized at\u00a0Taian 88 Hospital of China Rongtong Medical Healthcare Group Co. Ltd\u00a0between October 2016 and October 2024. Patients were divided into photosensitive and non-photosensitive groups based on\u00a0physician-confirmed PSN (defined as pathological skin reactions to ultraviolet radiation documented by at least two independent clinicians). Epidemiological, clinical, and immunological differences were compared, and PSN-associated factors were analyzed using SPSS 24.0.\u00a0Normality tests (Shapiro\u2013Wilk test) were performed for continuous variables; parametric tests (\n                      <jats:italic>t<\/jats:italic>\n                      -test) were used for normally distributed data, and non-parametric tests (Mann\u2013Whitney\n                      <jats:italic>U<\/jats:italic>\n                      -test) for non-normally distributed data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall PSN incidence in SLE patients was 36.59% (101\/276).\u00a0PSN was significantly more prevalent in female patients (95.05% vs. 86.86%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) and patients aged\u2009&lt;\u200940\u00a0years and 40\u201360\u00a0years (79.21% vs. 60.57%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05).\u00a0Median (interquartile range) age at diagnosis was 41.0 (29.0\u201354.0) years for the total cohort, 39.0 (28.0\u201352.0) years for the PSN group, and 44.0 (31.0\u201356.0) years for the non-PSN group.\u00a0PSN-SLE patients had a higher initial diagnosis accuracy (55.45% vs. 35.43%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Multivariate logistic regression identified rash (OR\u2009=\u200921.019, 95%CI 5.473\u201380.728), alopecia (OR\u2009=\u20095.940, 95%CI 1.658\u201321.281), arthritis (OR\u2009=\u20091.889, 95%CI 1.045\u20133.416), Raynaud syndrome (OR\u2009=\u20092.641, 95%CI 1.443\u20134.834), anti-Sm antibody (OR\u2009=\u20091.408, 95%CI 1.091\u20131.818), anti-SSA antibody (OR\u2009=\u20092.337, 95%CI 1.510\u20133.615), anti-SSB antibody (OR\u2009=\u20093.084, 95%CI 1.519\u20136.626), decreased C3 (OR\u2009=\u200914.308, 95%CI 3.526\u201358.061), decreased C4 (OR\u2009=\u20093.429, 95%CI 1.321\u20138.904), and RF positivity (OR\u2009=\u200910.640, 95%CI 2.173\u201352.093) as independent PSN-associated factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PSN is more common in female and young-to-middle-aged SLE patients. It correlates with distinct clinical (rash, alopecia, arthritis, Raynaud syndrome) and immunological (anti-Sm\/SSA\/SSB antibodies, decreased C3\/C4, RF positivity) features. Routine screening of these markers in PSN patients may facilitate early SLE diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-025-03795-7","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:46:33Z","timestamp":1767703593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A study of clinical manifestations and associated factors in photosensitive patients with systemic lupus erythematosus"],"prefix":"10.1186","volume":"31","author":[{"given":"Jia-huan","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-qi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Hui-Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-jing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"11","key":"3795_CR1","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1177\/0961203320941941","volume":"29","author":"A Su\u00e1rez-Avellaneda","year":"2020","unstructured":"Su\u00e1rez-Avellaneda A, Quintana JH, Arag\u00f3n CC, et al. Systemic lupus erythematosus in the intensive care unit: a systematic review. Lupus. 2020;29(11):1364\u201376.","journal-title":"Lupus"},{"issue":"5","key":"3795_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0961203317751852","volume":"27","author":"Z Wang","year":"2018","unstructured":"Wang Z, Li M, Wang Y, et al. Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in Chi5a. Lupus. 2018;27(5):864\u20139.","journal-title":"Lupus"},{"key":"3795_CR3","first-page":"15","volume-title":"China systemic lupus erythematosus development report 2020","author":"Z Xiaofeng","year":"2021","unstructured":"Xiaofeng Z, Mengtao Li, Xinping T, et al. China systemic lupus erythematosus development report 2020. Liaoning: Science and Technology Publishing House; 2021. p. 15\u201340."},{"issue":"34","key":"3795_CR4","first-page":"212","volume":"18","author":"GD Sebastiani","year":"2016","unstructured":"Sebastiani GD, Prevete I, Iuliano A, et al. The importance of an early diagnosis in systemic lupus erythematosus. Isr Med Assoc J. 2016;18(34):212\u20135.","journal-title":"Isr Med Assoc J"},{"issue":"9","key":"3795_CR5","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"22","key":"3795_CR6","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"MK Aringer","year":"2019","unstructured":"Aringer MK, Costenbader D, Daikh D, et al. 2019 European League against rheumatism American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(22):1151\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3795_CR7","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos GC, Marsc L, Pcosta R, et al. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Revheumatol. 2016;12(9):716\u201330.","journal-title":"Nat Revheumatol"},{"issue":"11","key":"3795_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classication of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271\u20137.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3795_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semarthrit.2020.11.006","volume":"51","author":"WM Lambers","year":"2021","unstructured":"Lambers WM, Westra J, Bootsma H, et al. From incomplete to complete systemic lupus erythematosus; a review of the predictive serological immune markers. Semin Arthritis Rheum. 2021;51(1):43\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"3795_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1191\/0961203304lu477oa","volume":"13","author":"CS Hallengren","year":"2004","unstructured":"Hallengren CS, Nived O, Sturfelt G, et al. Outcome of incomplete systemic lupus erythe matosus after 10 years. Lupus. 2004;13(10):85\u20138.","journal-title":"Lupus"},{"issue":"10","key":"3795_CR11","first-page":"1475","volume":"38","author":"WM Lambers","year":"2019","unstructured":"Lambers WM, Westra J, Jonkman MF, et al. Incomplete systemic lupus erythema- tosus what remains after application of ACR and SLICC criteria? Arthritis Care Res. 2019;38(10):1475\u201384.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"3795_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2034-4","volume":"21","author":"WM Lambers","year":"2019","unstructured":"Lambers WM, Leeuw K, van der Doornbos- Meer B, et al. Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin. Arthritis Res Ther. 2019;21(1):260.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3795_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/rheumatology\/40.1.89","volume":"40","author":"AJ Swaak","year":"2001","unstructured":"Swaak AJ, van de Brink H, Smeenk RJ, et al. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR standing committee on international clinical studies including therapeutic trials (ESCISIT). Rheumatology. 2001;40(1):89\u201394.","journal-title":"Rheumatology"},{"issue":"2","key":"3795_CR14","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288\u201391.","journal-title":"J Rheumatol"},{"issue":"5","key":"3795_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/BOR.0000000000000308","volume":"28","author":"JN Stannard","year":"2016","unstructured":"Stannard JN, Kahlenberg JM. Cutaneous lupus erythematosus: updates on patho genesis and associations with systemic lupus. Curr Opin Rheumatol. 2016;28(5):453\u20139.","journal-title":"Curr Opin Rheumatol"},{"issue":"66","key":"3795_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/0961203319839486","volume":"28","author":"J Ahluwalia","year":"2019","unstructured":"Ahluwalia J, Marsch A. Photosensitivity and photoprotection in patients with lupus erythematosus. Lupus. 2019;28(66):697\u2013702.","journal-title":"Lupus"},{"issue":"9","key":"3795_CR17","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.3389\/fimmu.2018.02430","volume":"23","author":"SJ Wolf","year":"2018","unstructured":"Wolf SJ, Estadt SN, Gudjonsson JE, et al. Human and murine evidence for mechanisms driving autoimmune photosensitivity. Front Immunol. 2018;23(9):2430.","journal-title":"Front Immunol"},{"issue":"4","key":"3795_CR18","volume":"12","author":"K Jatwani","year":"2020","unstructured":"Jatwani K, Chugh K, Osholowu OS, et al. Tumid lupus erythematosus and systemic lupus erythematosus: a report on their rare coexistence. Cureus. 2020;12(4):e7545.","journal-title":"Cureus"},{"issue":"2","key":"3795_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.mayocp.2019.09.012","volume":"95","author":"JS Nusbaum","year":"2020","unstructured":"Nusbaum JS, Mirza I, Shum J, et al. Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis. Mayo Clin Proc. 2020;95(2):384\u201394.","journal-title":"Mayo Clin Proc"},{"issue":"29","key":"3795_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/MD.0000000000004272","volume":"95","author":"KD Boodhoo","year":"2016","unstructured":"Boodhoo KD, Liu S, Zuo X, et al. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: systematic review and meta-analysis. Medicine. 2016;95(29):42\u201372.","journal-title":"Medicine"},{"issue":"18","key":"3795_CR21","first-page":"4096","volume":"24","author":"W Chen","year":"2013","unstructured":"Chen W, Yao C. Clinical characteristics of different age analysis of systemic lupus erythematosus. Modern Diagn Treat. 2013;24(18):4096\u20137.","journal-title":"Modern Diagn Treat"},{"issue":"2","key":"3795_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2174\/1871523018666181128161828","volume":"18","author":"AM Metry","year":"2019","unstructured":"Metry AM, Al Salmi I, Al Balushi F, et al. Systemic lupus erythematosus: symptoms and signs at initial presentations. Antiinflamm Antiallergy Agents Med Chem. 2019;18(2):142\u201350.","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"issue":"1","key":"3795_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.31138\/mjr.29.1.43","volume":"29","author":"S Ajmani","year":"2018","unstructured":"Ajmani S, Misra DP, Lawrence A. SLE presenting as migratory arthritis, chorea and nephritis. Mediterr J Rheumatol. 2018;29(1):43\u20135.","journal-title":"Mediterr J Rheumatol"},{"issue":"3","key":"3795_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-246484","volume":"15","author":"YN Kuo","year":"2022","unstructured":"Kuo YN, Lai CS, Chen YH, et al. Severe thoracic pyomyositis in a patient with systemic lupus erythematosus. BMJ Case Rep. 2022;15(3):e246484.","journal-title":"BMJ Case Rep"},{"issue":"11","key":"3795_CR25","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","volume":"77","author":"MK Sarkar","year":"2018","unstructured":"Sarkar MK, Hile GA, Tsoi LC, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77(11):1653\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"3795_CR26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526\u201333.","journal-title":"N Engl J Med"},{"issue":"23","key":"3795_CR27","first-page":"1186","volume":"13","author":"C Eriksson","year":"2011","unstructured":"Eriksson C, Kokkonen H, Johansson M, et al. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011;13(23):1186\u2013588.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"3795_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.autrev.2016.12.004","volume":"16","author":"GV Novak","year":"2017","unstructured":"Novak GV, Marques M, Balbi V, et al. Anti-RO\/SSA and anti-La\/SSB antibodies: association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus. Autoimmun Rev. 2017;16(2):132\u20135.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3795_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/08916934.2012.732131","volume":"46","author":"A Men\u00e9ndez","year":"2013","unstructured":"Men\u00e9ndez A, G\u00f3mez J, Escanlar E, et al. Clinical associations of anti-SSA\/Ro60 and anti-Ro52\/TRIM21 antibodies: diagnostic utility of their separate detection. Autoimmunity. 2013;46(1):32\u20139.","journal-title":"Autoimmunity"},{"issue":"3","key":"3795_CR30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1365-2133.1997.tb03655.x","volume":"136","author":"T Hasan","year":"1997","unstructured":"Hasan T, Nyberg F, Stephansson E, et al. Photosensitivity in lupus erythematosus, UV photoprovocation results compared with history of photosensitivityand clinical findings. Br J Dermatol. 1997;136(3):699\u2013705.","journal-title":"Br J Dermatol"},{"issue":"4","key":"3795_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1177\/0961203314524850","volume":"23","author":"M Fredi","year":"2014","unstructured":"Fredi M, Cavazzana I, Quinzanini M, et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus. 2014;23(4):672\u20137.","journal-title":"Lupus"},{"issue":"12","key":"3795_CR32","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/acr.24078","volume":"72","author":"Rheumatology\/European League Against Rheumatism Group","year":"2020","unstructured":"Rheumatology\/European League Against Rheumatism Group. Associations between classification criteria items in systemic lupus erythematosus. Arthritis Care Res. 2020;72(12):1820\u20136.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"3795_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5606\/ArchRheumatol.2019.6981","volume":"34","author":"F Yuan","year":"2018","unstructured":"Yuan F, Wei F, Huang H, et al. The predictive value of autoantibody spectrum on organ damage in patients with systemic lupus erythematosus. Arch Rheumatol. 2018;34(2):157\u201365.","journal-title":"Arch Rheumatol"},{"issue":"8","key":"3795_CR34","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1177\/0961203318759607","volume":"27","author":"A Fedrigo","year":"2018","unstructured":"Fedrigo A, Dos Santos TAFG, Nisihara R, et al. The lupus patient with positive rheumatoid factor. Lupus. 2018;27(8):1368\u201373.","journal-title":"Lupus"},{"issue":"4","key":"3795_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/1744666X.2020.1745063","volume":"16","author":"M Sharma","year":"2020","unstructured":"Sharma M, Vignesh P, Tiewsoh K, et al. Revisiting the complement system in systemic lupus erythematosus. Expert Rev Clin Immunol. 2020;16(4):397\u2013408.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"3795_CR36","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1177\/0961203318770016","volume":"27","author":"WD Abdul Kadir","year":"2018","unstructured":"Abdul Kadir WD, Jamil A, Shaharir SS, et al. Photoprotection awareness and practices among patients with systemic lupus erythematosus and its association with disease activity and severity. Lupus. 2018;27(8):1287\u201395.","journal-title":"Lupus"},{"issue":"8","key":"3795_CR37","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/0961203320930098","volume":"29","author":"T Janthongsri","year":"2020","unstructured":"Janthongsri T, Wisuthsarewong W, Nitiyarom R. Photoprotective habits in children with systemic lupus erythematosus. Lupus. 2020;29(8):964\u20139.","journal-title":"Lupus"},{"issue":"10","key":"3795_CR38","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1177\/0961203318768877","volume":"27","author":"A Ugarte","year":"2018","unstructured":"Ugarte A, Porta S, R\u00edos R, et al. Combined mepacrine-hydroxy chloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Lupus. 2018;27(10):1718\u201322.","journal-title":"Lupus"},{"issue":"1","key":"3795_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/cei.13180","volume":"194","author":"M Frodlund","year":"2018","unstructured":"Frodlund M, Vikerfors A, Grosso G, et al. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. Clin Exp Immunol. 2018;194(1):27\u201338.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"3795_CR40","first-page":"187","volume":"27","author":"W Fan","year":"2019","unstructured":"Fan W, Xuebing F, Lingyun S, et al. Antimalarials improve the survival of patients with systemic lupus erythematosus. Pharm Clin Res. 2019;27(3):187\u201390.","journal-title":"Pharm Clin Res"},{"issue":"1","key":"3795_CR41","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1186\/s13063-018-3076-7","volume":"19","author":"NJ Olsen","year":"2018","unstructured":"Olsen NJ, James JA, Arriens C, et al. Study of anti-malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018;19(1):694.","journal-title":"Trials"},{"issue":"2","key":"3795_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ajh.23609","volume":"89","author":"M Khellaf","year":"2014","unstructured":"Khellaf M, Chabrol A, Mahevas M, et al. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014;89(2):194\u20138.","journal-title":"Am J Hematol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03795-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:03:33Z","timestamp":1770131013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03795-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3795"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03795-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate: Approved by the Ethics Committee of Taian 88 Hospital of China Rongtong Medical Healthcare Group Co. Ltd (Ethical Approval ID: RTYL88-2023-099). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}